<table border="1"><tr><th>Médicament</th><td>Actinomycine D, bléomycine, docétaxel, témozolomide, dacarbazine, Aldesleukine | ( | d | ) | , procarbazine, lomustine | ( | en | ) | , hydroxyurée, dabrafenib, lambrolizumab, vemurafenib, cobimétinib | ( | en | ) | , nivolumab, bevacizumab, tramétinib | ( | en | ) | , paclitaxel, ipilimumab, peginterféron alfa-2b et sargramostim | ( | en | )</td></tr><tr><th>Spécialité</th><td>Oncologie</td></tr><tr><th>CISP-2</th><td>S77</td></tr><tr><th>CIM-10</th><td> C43</td></tr><tr><th>CIM-9</th><td> 172.9</td></tr><tr><th>ICD-O</th><td> M8720/3</td></tr><tr><th>OMIM</th><td> 155600</td></tr><tr><th>DiseasesDB</th><td> 7947</td></tr><tr><th>MedlinePlus</th><td> 000850</td></tr><tr><th>eMedicine</th><td>1100753 | med/1386ent/27 |  plastic/456</td></tr><tr><th>MeSH</th><td> D008545</td></tr></table>